MARKET

CGEN

CGEN

Compugen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.86
-0.42
-2.58%
After Hours: 15.86 0 0.00% 16:00 07/10 EDT
OPEN
16.45
PREV CLOSE
16.28
HIGH
16.69
LOW
15.78
VOLUME
738.68K
TURNOVER
--
52 WEEK HIGH
17.85
52 WEEK LOW
2.960
MARKET CAP
1.26B
P/E (TTM)
-40.3152
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CGEN stock price target is 18.88 with a high estimate of 28.00 and a low estimate of 13.00.

EPS

CGEN News

More
iTeos Therapeutics Begins U.S. IPO Rollout
Seeking Alpha - Article · 07/02 19:59
Hedge Funds Have Never Been This Bullish On Compugen Ltd. (CGEN)
Insider Monkey · 06/22 19:40
Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/03 08:39
Cramer Weighs In On Ciena, Harley-Davidson And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes Gary Smith, the CEO of Ciena Corporation (NYSE: CIEN). He thinks Ciena and the CEO rock.
Benzinga · 06/02 11:14
Cramer's lightning round: Harley-Davidson is not a buy
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 06/01 23:18
FDA clears Compugen's IND for Phase 1/2 triple combination study
Seeking Alpha - Article · 06/01 12:58
Compugen on go with study of cancer triplet therapy
Seeking Alpha - Article · 06/01 12:58
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
PR Newswire · 06/01 12:00

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About CGEN

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
More

Webull offers kinds of Compugen Ltd. (USA) stock information, including NASDAQ:CGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CGEN stock methods without spending real money on the virtual paper trading platform.